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Abstract 21 22
Sea spray aerosols (SSAs) have profound effects on climate and ecosystems. Furthermore, the 23 presence of microbiota and biogenic molecules, produced by among others marine phytoplankton, in 24
SSAs could lead to potential human health effects. Yet the exposure and effects of SSAs on human 25 health remain poorly studied. Here, we exposed human epithelial lung cells to different concentrations 26 of extracts of a natural sea spray aerosol (SSA), a laboratory-generated SSA, the marine algal toxin 27 homoyessotoxin and a chemical mTOR inhibitor. The mTOR inhibitor was included as it has been 28 hypothesized that natural SSAs may influence the mTOR cell signaling pathway. We observed 29 significant effects on the mTOR pathway and PCSK9 in all exposures. Based on these expression 30 patterns, a clear dose response relationship was observed. Our results indicate a potential for positive 31 health effects when lung cells are exposed to environmentally relevant concentrations of natural SSAs, 32 Introduction 40 41
Oceans and seas contain a variety of biogenic or naturally produced molecules that become airborne 42 via sea spray aerosolization 1-3 . In addition to bacteria, which are well-known producers of biogenics, 43 many phytoplankton species also produce a wide range of bioactive molecules such as vitamins, 44 pigments, polyphenolics and phycotoxins 4,5 . The latter have primarily been studied in the context of 45 harmful algal blooms, in which phycotoxins can be present at detrimental concentrations 4,6 . These 46 toxins can through their presence in sea spray aerosols cause health effects. This has been reported 47 for aerosolized brevetoxins which can lead to respiratory symptoms in humans during algal bloom 48 conditions, particularly in people with asthma 7,8 . 49
The effects of brevetoxins have been well-studied and documented. Little attention has, however, 50 been given to the potential effects at low, environmentally relevant, concentrations in which 51 phycotoxins may be present in sea spray aerosols (SSAs) during standard environmental conditions 9 . 52 At low levels, and combined with other unidentified biogenics, these known bioactive molecules could 53 contribute to positive health effects in coastal environments. Indeed, some of these bioactive 54 molecules (e.g. yessotoxin 10 ) have been targeted for their pharmaceutical or biotechnological 55 potential 11, 12 . Furthermore, a number of studies highlight several health promoting pathways through 56 which airborne microbiota and biogenics from blue and green environments may have positive health 57 effects 13, 14 . Airborne microbiota are thought to contribute to a more effective immuno-regulation once 58 inhaled or ingested 13 . Additionally, it was suggested that inhalation of low levels of microbes and 59 parasites reduce inflammation and improve immunoregulation 13, 15 . Biogenics, i.e. natural chemicals 60 produced by among others plants, fungi, phytoplankton species and bacteria 1,3,9 , have been 61 hypothesized to induce positive health effects via the interaction with specific cell signaling pathways 62 (e.g. PI3K/Akt/mTORC1) 14 . The link between the mTOR pathway and positive health effects is 63 supported by a large number of studies [16] [17] [18] [19] [20] demonstrating that inhibition of this cell signaling pathway 64 is associated with health benefits such as anti-cancer, positive cardiovascular and anti-inflammatory 65
effects. 66
To date, no study has focused on the general health effects of SSAs under standard coastal conditions. 67
Here, we aimed to explore possible molecular mechanisms that could explain health effects of SSAs at 68 different concentrations representing low environmentally relevant concentrations as well as high 69 potential harmful concentrations. To this end, we exposed human epithelial lung cells to extracts of 70
(1) a natural SSA, (2) a SSA generated in a laboratory tank inoculated with homoyessotoxin-producing 71 algae, (3) the pure bioactive molecule homoyessotoxin (hYTX) and (4) a chemical inhibitor of the mTOR 72 pathway (Torkinib/PP242). We specifically selected hYTX and a hYTX producer as the effects of hYTX 73 in humans remain relatively unknown despite it being structurally related to brevetoxin 10 . In addition, 74 yessotoxin has been reported to show potential as an anti-cancer drug 10 . As such, aerosols of this 75 phycotoxin could be a source of positive health effects. The different treatments, including different 76 dose levels per treatment, allowed us to study a range of conditions, from most realistic, i.e. natural 77 SSA, to the simplest, i.e. a single biogenic molecule (homoyessotoxin). 78
Results & Discussion

79
A small set of genes is significantly differentially expressed in all treatments. We quantified the 80 expression of 16,5654 genes and observed differential expression across all treatments. The highest 81 number of differentially expressed (DE) genes was observed in the pure homoyessotoxin treatment, 82 hereafter referred to as hYTX. We observed a decreasing number of differentially expressed genes in 83 the chemical inhibitor treatment, hereafter referred to as mTOR inhibitor, the natural SSA treatment 84 and the treatment with a SSA generated in a laboratory tank, hereafter referred to as lab SSA. We 85 observed almost no significant DE genes in the mid and low dose levels at false discovery rates (FDR) 86 of 0.01 and 0.05 ( Figure 1A) . Given the small difference between the two FDRs, the most conservative 87 FDR was selected for further analysis. We identified two DE genes shared by all (high dose level) 88 treatments and the mTOR inhibitor ( Figure 1B The first gene was the small integral membrane protein 29 (SMIM 29). Little functional information on 97 this protein is available, although it is ubiquitously expressed in at least 25 tissues 21 . The other gene is 98 proprotein convertase subtilisin/kexin type 9 (PCSK9), primarily involved in lipid homeostasis and 99 apoptosis 22 . For SMIM 29, we observed a similar pattern across all treatments with low gene 100 expression values in low and mid dose levels, and a significant upregulation in all high dose level 101 treatments and the mTOR inhibitor ( Figure 1C ). For PCSK9, the pattern is more complex. Again, we 102 observed low gene expression values at low and mid dose levels. However, for the high dose levels, 103
we observed a significant upregulation for hYTX and the lab SSA, while we observed a significant 104 downregulation for the natural SSA treatment and the mTOR inhibitor ( Figure 1C ). For both PSCK9 and 105 SMIM29 the effects of the lab SSA were similar but weaker than the effects of the hYTX itself. 106 Furthermore, all DE genes that were significantly regulated by the lab SSA are a subset of the DE genes 107 regulated by hYTX. This suggests that the effects of the lab SSA are most likely comparable to effects 108 of a diluted hYTX treatment. Or, in other words, the effects of the lab SSA produced by a hYTX 109 producing algae are weaker than the effects of hYTX itself despite containing the same amount of hYTX. 110
Given that the dose levels for both treatments (lab SSA and hYTX) contain the same amount of hYTX, 111 these results suggest that (1) lab SSAs may contain additional molecules which interact with hYTX 112 leading to weaker effects or that (2) some of the hYTX in the lab SSA is partially degraded leading to 113 potentially weaker effects as less "pure" hYTX is available. Literature reports only briefly on the organic 114 composition of SSAs, but suggests a large diversity in biogenic compounds 23,24 . PCSK9 is thought to 115 have two major functions: (1) maintenance of lipid homeostasis by the regulation of low-density 116 lipoprotein receptors and (2) the regulation of neural apoptosis 22 . In general, the overexpression of 117 PCSK9 is associated with the dysregulation of pathways involved in the cell cycle, inflammation and 118 apoptosis while the inhibition of PCSK9 in carcinogenic lung cells has been associated with apoptosis 119 of these cell lines 22 . In mouse, a similar pattern has been observed 25 . Overexpression of PCSK9 was 120 associated with multi-organ pathology and inflammation while PCSK9 deficiency was associated with 121 protection against inflammation, organ pathology and systemic bacterial dissemation 25 . Based on 122 these findings in literature and the similarities between the PCSK9 expression patterns of the mTOR 123 inhibitor and the natural SSA, our results suggest a potential for positive health effects when lung cell 124 lines are exposed to natural SSA. Based on the results provided here on PCSK9, we propose that SSA 125 contain molecules with significant pharmaceutical potential in targeting PCSK9 26 . 126
Significant effects on the mTOR regulatory pathways differ across treatments. The biogenics 127
hypothesis suggests that the mTOR pathway is one of the key drivers of the coastal induced health 6 benefit. Here both the KEGG mTOR pathway annotation 27 and the molecular signature databases 28 , 129 which contains a hallmark set of genes upregulated upon activation of the mTORC1 complex, were 130 used to test this hypothesis. No significant enrichment of the KEGG mTOR pathway in any of the 131 treatments was observed. Individual genes of the mTOR pathway, however, were significantly 132 regulated in different high dose treatments, with the exception of the lab SSA for which no mTOR 133 genes were differentially expressed (Table S1 ). We also noted significant enrichment scores of the 134 GSEA Hallmark mTORC1 set for all high dose treatments, excluding the natural SSA, and the mTOR 135 inhibitor (Table S2 ). Taking a closer look at the hallmark mTORC1 set, we concluded that the gene 136 expression patterns differed across treatments ( Figure S1 ). Hierarchical clustering of these patterns 137 indicated that DE genes were in general regulated in the opposite direction for hYTX and the lab SSA 138 versus the natural SSA and the chemical inhibitor ( Figure S1 ). This pattern is even more prominent 139 when focusing on the genes that contribute significantly to the enrichment score in the hallmark set 140 for all 4 treatments ( Figure 2 ). 141 This group of 17 genes showed completely opposite regulation patterns in the high dose hYTX versus 148 the high dose natural SSA and the chemical inhibitor ( Figure 2 ). The high dose laboratory SSA showed 149 a similar but less intense and weaker regulation than the high dose pure hYTX. Overall, these results 150 suggest that all treatments affect the mTOR pathway but the effects and the potential positive health 151 effects differ across treatments. Interestingly, the effects of the natural SSA closely resemble the 152 effects of the mTOR inhibitor, but contrast with the effects of hYTX and the lab SSA. In addition, we 153 again observed that the lab SSA caused effects in a similar direction as the pure hYTX, albeit weaker. 154
The differences between the natural SSA on one hand and the pure hYTX and lab SSA on the other 155 hand highlight that while all treatments target the mTOR pathway, their effects are opposite. This may 156 suggest (1) that the natural SSA contains different molecules than the lab SSA and hYTX or (2) that less 157 "pure" hYTX is available due to degradation of hYTX. Both assumptions suggest a lower bioavailability 158 of pure hYTX, potentially leading to a lower actual dose. This is also supported by the observation that 159 six genes of the mTOR pathway show a significant dose response effect (Table S2 ). The similarities in 160 regulation of the mTOR pathway between the natural SSA and chemical inhibitor suggest that natural 161 SSAs contain molecules that cause similar effects on the mTOR pathway as the chemical inhibitor. 162
Significant concentration response patterns across treatments. We observed a total of 1898 genes 163 with a significant dose response effect across the three treatments (hYTX, lab SSA and natural SSA). 164
Based on a regression analysis and clustering, we found four clusters of dose response patterns. These 165 clusters all show the same trend which consists of a steep dose response curve for hYTX while the lab 166 SSA and the natural SSA show a slower increase ( Figure S2 ). When observing gene expression patterns 167 for the clusters across all treatments, we see the same pattern of two groups as reported in the 168 sections above, one containing the high dose hYTX and lab SSA treatment while the other contains the 169 remaining treatments. In three of the four clusters, the mTOR inhibitor treatment clustered together 170 with the high dose natural SSA treatment. These clustering results suggest that the observations we 171 have made above for the mTOR pathway and PCSK9 gene are not limited to these two observations 172 but can be extended to all genes with a significant dose response effect. A pathway analysis highlighted 173 four pathways that were enriched for genes with a significant dose response effect (Table S3 ). These 174 pathways are the spliceosome, lysosome, steroid biosynthesis and glycogenesis. For all these 175 pathways, we observed two major clusters ( Figure 3A-D, Figures S3-6) : the pattern for the highest dose 176 hYTX was again similar to that of the highest dose lab SSA while the pattern of the natural SSA was 177 again similar to that of the mTOR inhibitor. Again, we observed the opposite regulation of genes in 178 these two groups for three pathways. Indeed, for the lysosome, steroid biosynthesis and glycogenesis 179 pathways we noted an upregulation of genes with a significant dose-response effect in the high dose 180
hYTX and the high dose lab SSA ( Figure 3B-D) . In contrast, for these same pathways, we observed 181 primarily a downregulation of the same significant genes in the mid and low dose hYTX and lab SSA, as 182 well as all natural SSA treatments and the chemical inhibitor with the exception of the low lab SSA in 183 the glycogenis pathway. For the spliceosome, we observed significant upregulation in all treatments 184 with exception of the low and mid hYTX and mid lab SSA ( Figure 3A) . 185 Similar to the effects in the mTOR pathway, the effects on these pathways again show a similar 192 regulation of genes for the natural SSA and the mTOR inhibitor. For the steroid biosynthesis, these 193 results are not surprising given the links that have already been discussed above between mTOR and 194 lipid biosynthesis. In addition to steroid biosynthesis, the lysosome and glycogenesis also have links to 195 mTOR. The inhibition of the mTOR pathway is known to activate protein degradation and autophagy 196 through among others the lysosome 29,30 . The spliceosome has been proposed as a therapeutic target 197 in cancer cells to inhibit mTOR, which led to autophagy 31 . Specifically, depletion of small nuclear 198 ribonucleoprotein polypeptide E (SNRPE) led to reduced cell viability in lung cancer cell lines. Here, we 199 observed in addition to dose response effects for the spliceosome, also a significant downregulation 200 of SNRPE in the highest hYTX treatment but not in any of the other treatments (Table S4 ). Overall, the 201 pathways with significant dose response effects can all be indirectly linked to the mTOR pathway, 202 suggesting that the effects here are a consequence of the effects on the mTOR pathway, which most 203 likely induce a cascade of events and interactions with other pathways. 204
Significant effects unique to hYTX and sea spray aerosols. While we have focused on similarities 205 between effects of our experimental treatments and the mTOR inhibitor, we also observed effects 206 unique to these treatments. We observed the differential expression of three genes shared by all high 207 dose treatments. These genes are stearoyl-CoA desaturase (SCD), cytochrome P450 family 1 subfamily 208 B member 1 (CYP1B1) and peptidyl arginine deiminase 3 (PADI3). For SCD, we observed a pattern 209 similar to that of the PCSK9 expression, i.e. exposure to the natural SSA led to downregulation while 210 exposure to the lab SSA and hYTX led to upregulation ( Figure 4A ). This can be attributed to the 211 functions of these genes (i.e. SCD, PCSK9), as both are involved in lipid biosynthesis. Furthermore, 212 research has already indicated links between the mTOR pathway and the lipid homeostasis 32 , including 213 the effects on SCD and other genes after exposure to mTOR inhibitors 32 . Evidence points to sterol 214 regulatory element binding transcription factor 1 (SREBF1) through which the regulation of lipogenesis 215 by mTOR is achieved 32 . This gene was significantly regulated by the natural SSA, but not by any of the 216 other treatments. For CYP1B1 and PADI3, we observed a pattern similar as for SMIM29, in which all treatments resulted 224 in significant upregulation ( Figure 4B-C) . The first is commonly involved in the metabolism of 225 xenobiotics and could play a role in metabolizing some of the biogenic molecules. Literature has also 226 reported a relation between CYP1B1 and SCD in lipid homeostasis in liver cells 33 , although the extent 227 of this relation in lung cells remains unclear. Overexpression of CYP1B1 has also been reported in lung 228 cell lines through the aryl hydrocarbon receptor 34 , but no significant effects for this receptor were 229 observed in any treatment of our study (Table S4 ). This suggests that the overexpression of CYP1B1 is 230 more likely related to the regulation of SCD. Lastly, we observed a significant upregulation of PADI3 in 231 all three high dose treatments (hYTX, lab SSA and natural SSA). PADI3 is generally not expressed in lung 232 cells 21 and is primarily expressed in epidermis cells and keratinocytes 35 . Its function in lung cell lines 233 remains unclear. Overall, we observe here differential expression of genes linked to the mTOR pathway 234 in all three high dose treatments (natural SSA, lab SSA, and hYTX). Most likely, the effects on these 235 genes are caused by the primary effects on the mTOR pathway. Furthermore, these effects while linked to the mTOR pathway, are not observed with the mTOR inhibitor. This suggests that the effects of 237 these experimental treatments (natural SSA, lab SSA, and hYTX) extend beyond the inhibition of mTOR 238 but are related to or initiated by the effects on the mTOR pathway. 239
Differences in dose level lead to a different regulation of the same significant genes and pathways 240 across treatments. The results of gene set and pathway enrichments as well as individual genes 241 highlight that the effects are primarily mediated or linked through the mTOR pathway ( Figure 5) . Here, 242
we studied both a natural and a lab SSA, as well as the effects of pure hYTX as potential key biogenic 243 molecule in natural SSAs. While we observed similar pathways, and to some extent, similarly affected 244 genes across these different treatments, the regulation was not necessarily the same. The hYTX and 245 the lab SSA showed a similar pattern across all pathways and genes, while differences were observed 246 with the natural SSA and the chemical inhibitor. These differences could be related to the differences 247 in doses. The high dose treatment for both hYTX and lab SSA of 0.5 µg liter -1 is an extreme case scenario, 248 reflecting concentrations in water during harmful algal blooms (supportive information 1.2). The 249 environmental (background) concentrations of hYTX in water and air have not been previously 250 reported but are expected to lie between the low and mid dose levels based on estimates of cell counts 251 of hYTX producers and hYTX production per cell (supportive information 1.2). As such, it is clear that 252 there is a switch in effects where at high doses hYTX and lab SSAs can cause negative effects while the 253 regulation of pathways and genes is the opposite at low and mid doses, suggesting positive health 254 effects at environmentally relevant (background) concentrations. A direct comparison can only be 255 made with the lab SSA in terms of total aerosols by using the cation sodium as a proxy for 256 aerosolization 36 . We observed that the lab SSA dose levels are 2.8 µg Na + well -1 , 0.06 µg Na + well -1 and 257 0.00006 µg Na + well -1 while the natural SSA dose levels, due to the smaller sample size, were 0.6 µg 258 Na + well -1 , 0.14 µg Na + well -1 and 0.014 µg Na + well -1 (section 1.2). As such, the highest dose for the 259 natural SSA contains only 20% of the amount of aerosols in the high dose lab SSA treatment. This 260 supports the assumptions made above that exposure to environmentally relevant concentrations of 261 marine biogenics, sampled from the environment, can lead to positive health effects at 262 environmentally relevant concentrations. In addition, we observed similar patterns of gene expression 263 for the mTOR inhibitor and the highest natural SSA treatment. 264
Overall, our results support the biogenesis hypothesis postulated by Moore 14 that marine airborne 265 biogenics interact with the mTOR pathway potentially leading to health benefits. We report significant 266 effects on the mTOR pathway in all treatments, though differences in regulation of this pathway were 267 observed. Furthermore, significant genes and enriched pathways across treatments all interact with 268 mTOR, indicating that marine biogenics trigger a cascade of events through interaction with the mTOR 269 pathway ( Figure 5) .Thus, the effects of marine airborne biogenics are not limited to the mTOR pathway but include a cascade of genes and pathways involved in different metabolic processes (e.g. steroid 271 biosynthesis, lysosome) with key links to mTOR (Figure ) . penicillin-streptomycin at 37°C, 5% CO2 and >95% relative humidity. Confluent cell cultures (after 2-3 281 days) were passaged via trypsination (0.5% trypsin-EDTA) and split in a ratio 1:6. 282
Experimental procedure. Confluent cell cultures were trypsinized and transferred in 3mL fresh DMEM 283 to Nunc 6-well multiplates at a density of 320,000 cells.well -1 . After seeding, cells were incubated for 284 10 hours at 37°C, 5% CO2 and >95% relative humidity to stimulate growth and adherence to the 285 surface. Then, cells were subjected to one of five treatments: (1) negative control, (2) an extract of a 286 natural SSA sample from the seashore, (3) an extract of a laboratory generated SSA, 287
(4) homoyessotoxin, (5) a chemical inhibitor of the mTOR pathway, i.e. Torkinib or PP242 288 (LC Laboratories). The multiwell plates were then incubated for another 43 hours at identical 289 conditions prior to RNA extraction. The negative control treatment also contained 2% methanol to 290 exclude a solvent effect as all other treatments were extracted, diluted or dissolved in methanol. The 291 chemical inhibitor treatment consisted of 0.3 µM of Torkinib or PP242. The natural sea spray aerosol 292 sample was collected on a Whatman QM-A Quartz Microfiber filter at the waterline close to Ostend, 293 Belgium (51°14'27"N, 2°56'10"E) by sampling for 46 minutes at a flow of 10 L min -1 , which corresponds 294 to the minute ventilation of an average human in rest (9-10 L min -1 ) 37,38 . During sampling, the wind 295 direction was 0.7 ± 3.1 ° (North), speed was 15.0 ± 0.6 m s -1 , indicating white cap SSA production. The 296 detailed sampling and extraction procedure is described in supportive information 1.1. The lab SSA 297 was obtained by inoculating a marine aerosol reference tank 39 with 10 6 cells L -1 of Protoceratium 298 reticulatum, a hYTX producer (SCCAP K-1474), and collecting the generated SSA on a Whatman QM-A 299
Quartz Microfiber filter at a flow of 10 L min -1 for 16 hours to obtain sufficient material for further 300 experiments and analysis. The detailed procedure is described in supportive information 1.1. Filters of 301 the natural SSA and lab SSA were extracted following the same methanol extraction procedure. 302
Certified reference material of hYTX was commercially obtained (National Research Council Canada) 303 as a liquid with a concentration of 5µM hYTX dissolved in methanol. This reference material was further 304 diluted in methanol to obtain the following dose levels: 0.5 µg L -1 (high), 0.01 µg L -1 (mid), 0.00001 µg 305 L -1 (low). Concentrations of hYTX in the lab SSA were measured using ultra-high-performance liquid 306 chromatography high-resolution Orbitrap mass spectrometry following procedures as reported by 307 Orellana et al. (2014) 40 . To allow an optimal comparison between the hYTX treatment and the lab SSA, 308 the lab SSA dose levels were determined based on the measured hYTX in these samples and the same 309 dose levels as the hYTX treatment were selected (0.5 µg L -1 (high), 0.01 µg L -1 (mid), 0.00001 µg L -1 310 (low)). For natural SSA, low, mid and high doses were determined by comparing the total alveolar 311 surface with the cell surface available in a single well (9.6 cm²) and comparing the sample collection 312 duration (46 min) and experimental exposure duration (43 h), see supportive information 1.2. We 313 selected a low dose that represents the same exposure as the amount of inhaled SSA during the 314 sampling period at the seashore but extended over an 43 h exposure period and normalized to the cell 315 surface in a single well (detailed calculations are reported in supportive information, section 1.2). The 316 mid and high dose represent a 10x and 40x concentration of the low dose level. These levels were 317 specifically chosen to adhere to environmentally realistic (background) concentrations. The mid dose 318 level (10x concentration) was based on the hypothesis of increased minute ventilation during physical 319 exercise which is reported to vary between 70-100 L min -1 for both continuous and intermittent 320 exercise 38,41,42 . The high dose level (40x concentration) was selected based on the hypothesis of 321 increased aerosolization (i.e. improved wind conditions) as well as activities at the shore line or at sea 322 (e.g. swimming, sailing, windsurfing,..,..). Detailed procedure is described in the supportive 323 information, section 1.2. 324 RNA extraction, library preparation and sequencing. RNA was extracted using the Qiagen RNEasy kit 325 following the manufacturer's instructions including DNAse digestion. After RNA extraction, the 326 concentration and quality of the total extracted RNA was checked by using the 'Quant-it ribogreen RNA 327 assay' (Life Technologies, Grand Island, NY, USA) and the RNA 6000 nano chip (Agilent Technologies, 328 Santa Clara, CA, USA), respectively. Subsequently, 250 ng of RNA was used to perform an Illumina 329 sequencing library preparation using the QuantSeq 3' mRNA-Seq Library Prep Kits (Lexogen, Vienna, 330 Austria) according to manufacturer's protocol. During library preparation 14 PCR cycles were used. Data analysis. Per sample, on average 7.5 x 10 6 ± 1.6 x 10 6 reads were generated. First, these reads 337 were trimmed using cutadapt 43 version 1.15 to remove the "QuantSEQ FWD" adaptor sequence. The 338 trimmed reads were mapped against the Homo sapiens GRCh38.89 reference genome using STAR 44 339 version 2.5.3a. The RSEM 45 software, version 1.3.0, was used to generated the count tables. 340 Differential gene expression analysis between groups of samples was performed using edgeR 46 . Genes 341 with less than 1 cpm in less than 4 samples were discarded, resulting in 16,546 quantifiable genes. 342
Read counts were normalized using trimmed mean of M-values (TMM) followed by a pairwise 343 comparison of treatments with the negative and positive control using an exact test 46 . Significantly 344 differentially expressed (DE) genes were called at a false discovery rate of 0.01. Significant enrichment 345 of KEGG pathways 27 with DE genes was done using a fisher test and called at an adjusted p-value level 346 of 0.01. Benjamini-Hochberg adjustment was used to account for multiple testing. Gene set 347 enrichment analysis (GSEA) was conducted to detect enrichment in hallmark gene sets and genetic and 348 chemical perturbations gene sets of the molecular signature database 28 . Enriched gene sets were 349 identified at a false discovery rate of 0.01. A dose response analysis was performed with the maSigPro 47 350 R package for each of the three treatments of algal toxins. In a first step a general linear model was 351 built with the 3 treatments, the 3 concentrations and the square of each of the 3 concentrations. 352
Statistical testing was done using the log-likelihood ratio statistic. Genes with a FDR < 0.05 were 353 considered significantly differential. In a second step, for each significant differentially expressed gene, 354 an optimized regression model was created using stepwise backward regression. Exclusion of the 355 quadratic term from the model was performed using a regression ANOVA, testing if the regression 356 coefficients differ from 0 at a significance level of 0.05. Afterwards the goodness of fit, R², of each 357
